214699-26-0

Basic information

• Product Name: 5,6,7,8-TETRAHYDRO-6-(PHEHYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE
• Synonyms: 5,6,7,8-TETRAHYDRO-6-(PHEHYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE;5,6,7,8-Tetrahydro-6-(phenylmethyl)-1,6-naphthyridin-3-amine;3-Amino-6-benzyl-5,6,7,8-tetrahydro-1,6-naphthyridine
• CAS NO: 214699-26-0
• Molecular Formula: C₁₅H₁₇N₃
• Molecular Weight: 239.31558
• Mol File: 214699-26-0.mol

Chemical Properties

• Boiling Point: 421.8 °C at 760 mmHg
• Flash Point: 208.9 °C
• Appearance: /
• Density: 1.189
• Vapor Pressure: 2.53E-07mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6?+-.0.20(Predicted)
• CAS DataBase Reference: 5,6,7,8-TETRAHYDRO-6-(PHEHYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-TETRAHYDRO-6-(PHEHYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE(214699-26-0)
• EPA Substance Registry System: 5,6,7,8-TETRAHYDRO-6-(PHEHYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE(214699-26-0)

Safety Data

• Hazardous Substances Data: 214699-26-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,6,7,8-TETRAHYDRO-6-(PHENYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE is used as a building block for the synthesis of pharmaceutical compounds due to its unique chemical structure and potential bioactive properties. Its presence in the development of novel drugs allows for targeting a wide range of diseases, making it a crucial component in the advancement of medical treatments.
Used in Drug Discovery and Development:
As a valuable intermediate, 5,6,7,8-TETRAHYDRO-6-(PHENYLMETHYL)-1,6-NAPHTHYRIDIN-3-AMINE is utilized in drug discovery and development processes. Its incorporation into new drug molecules can lead to the creation of innovative therapeutic agents with improved efficacy and selectivity, contributing to the ongoing efforts in addressing unmet medical needs and enhancing patient care.

InChI:InChI=1/C15H17N3/c16-14-8-13-11-18(7-6-15(13)17-9-14)10-12-4-2-1-3-5-12/h1-5,8-9H,6-7,10-11,16H2

Upstream product

• 214699-24-8 6-benzyl-3-nitro-5,6,7,8-tetrahydro[1,6]naphthyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 625098-87-5 C₁₅H₁₆N₂O 

Relevant articles and documents

An expeditious synthesis of 3-(difluoromethoxy)- and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines

An expeditious and concise synthesis of 3-(difluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridine and 3-(trifluoromethoxy)-5,6,7,8-tetrahydro-1,6-naphthyridines is described. Starting from N-benzyl piperidone, the key intermediates leading to these two bio

Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists

SCH 58261 is a reported adenosine A2A receptor antagonist which is active in rat in vivo models of Parkinson's Disease upon ip administration. However, it has poor selectivity versus the A1 receptor and does not demonstrate oral activity. Quinoline analogs have improved upon the selectivity and pharmacokinetics of SCH 58261, but were difficult to handle due to poor aqueous solubility. We report the design and synthesis of fused heterocyclic analogs of SCH 58261 with aqueous solubility as well as improved A2A receptor binding selectivity and pharmacokinetic properties. In particular, the tetrahydronaphthyridine 4s has excellent A2A receptor in vitro binding affinity and selectivity, is active orally in a rat in vivo model of Parkinson's Disease, and has aqueous solubility of 100 μM at physiological pH.

A facile synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system and some alkylated and polycyclic homologues

A facile, two step synthesis of the 3-amino-5,6,7,8-tetrahydro[1,6]naphthyridine system 1 and its more substituted homologues 2-5 via the condensation of mono- and bicyclic-4-piperidinones 11a-c, 12-14 with 3,5-dinitro-1-methyl-2-pyridone 6 in the presenc

Imidazole and imidazoline derivatives and uses thereof

This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human α2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where